GlaxoSmithKline Biologicals (GSK Bio) and Crucell NV (Johnson & Johnson) have announced a collaboration to develop a vaccine approach aimed at boosting the efficacy of the world’s most clinically advanced malaria vaccine candidate, RTS,S. The PATH Malaria Vaccine Initiative (MVI) today congratulated the companies on the partnership. "We are excited by the potential of this new endeavor for … [Read more...]
Sanaria Wins $3M Grant for Development of Malaria Vaccine
Sanaria has won a three-year, $3 million phase 2 Small Business Research Innovation grant from the National Institutes of Health to further develop its malaria vaccine. The money will support research by scientists at the Rockville company and its partner, Columbia University, according to Sanaria information. The new grant continues earlier NIH-supported efforts at Sanaria and Columbia to … [Read more...]